Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rofecoxib - Merck & Co.

Drug Profile

Rofecoxib - Merck & Co.

Alternative Names: Ceoxx; MK 966; Vioxx; Vioxx Acute

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Banyu; CollaGenex Pharmaceuticals; Merck & Co; Merck Frosst
  • Class Antirheumatics; Lactones; Non-opioid analgesics; Sulfones
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Dental pain; Dysmenorrhoea; Musculoskeletal disorders; Osteoarthritis; Pain; Rheumatoid arthritis
  • Discontinued Alzheimer's disease; Colorectal cancer; Familial adenomatous polyposis; Juvenile rheumatoid arthritis; Migraine; Periarthritis; Preterm labour; Sporadic adenomas

Most Recent Events

  • 21 Feb 2005 An advisory committee of the FDA has recommended that the risk-benefit profile for rofecoxib supports marketing in the USA
  • 11 Oct 2004 A clinical study has been added to the adverse events section
  • 01 Oct 2004 Discontinued - Clinical-Phase-Unknown for Juvenile rheumatoid arthritis in Europe (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top